Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Ocular Therapeutix's total debt was $72.80M at Jun 30, 2026. For fiscal 2025 it was $71.34M, up 4.1% from the year before. Over ten years it grew 16.7% a year on average. The highest annual figure on record is $71.34M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.34M | +4.1% |
| FY2024 | Dec 31, 2024 | $68.51M | +4.1% |
| FY2023 | Dec 31, 2023 | $65.79M | +160.5% |
| FY2022 | Dec 31, 2022 | $25.26M | +1.0% |
| FY2021 | Dec 31, 2021 | $25.00M | +47.6% |
| FY2020 | Dec 31, 2020 | $16.94M | -32.3% |
| FY2019 | Dec 31, 2019 | $25.01M | +0.9% |
| FY2018 | Dec 31, 2018 | $24.79M | +98.8% |
| FY2017 | Dec 31, 2017 | $12.47M | -11.5% |
| FY2016 | Dec 31, 2016 | $14.09M | -7.7% |
| FY2015 | Dec 31, 2015 | $15.27M | +13.0% |
| FY2014 | Dec 31, 2014 | $13.51M | +1975.4% |
| FY2013 | Dec 31, 2013 | $651.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $72.80M | +4.1% |
| Q1 FY2026 | Mar 31, 2026 | $72.06M | +4.1% |
| Q4 FY2025 | Dec 31, 2025 | $71.34M | +4.1% |
| Q3 FY2025 | Sep 30, 2025 | $70.62M | +4.1% |
| Q2 FY2025 | Jun 30, 2025 | $69.91M | +4.1% |
| Q1 FY2025 | Mar 31, 2025 | $69.20M | +4.1% |
| Q4 FY2024 | Dec 31, 2024 | $68.51M | +4.1% |
| Q3 FY2024 | Sep 30, 2024 | $67.82M | +4.1% |
| Q2 FY2024 | Jun 30, 2024 | $67.13M | +188.1% |
| Q1 FY2024 | Mar 31, 2024 | $66.46M | +162.5% |
| Q4 FY2023 | Dec 31, 2023 | $65.79M | +160.5% |
| Q3 FY2023 | Sep 30, 2023 | $65.12M | +158.5% |
| Q2 FY2023 | Jun 30, 2023 | $23.30M | -7.3% |
| Q1 FY2023 | Mar 31, 2023 | $25.32M | +1.0% |
| Q4 FY2022 | Dec 31, 2022 | $25.26M | +1.0% |
| Q3 FY2022 | Sep 30, 2022 | $25.19M | +1.0% |
| Q2 FY2022 | Jun 30, 2022 | $25.13M | +1.0% |
| Q1 FY2022 | Mar 31, 2022 | $25.06M | +68.1% |
| Q4 FY2021 | Dec 31, 2021 | $25.00M | +47.6% |
| Q3 FY2021 | Sep 30, 2021 | $24.94M | +31.5% |
| Q2 FY2021 | Jun 30, 2021 | $24.89M | +18.7% |
| Q1 FY2021 | Mar 31, 2021 | $14.91M | -35.2% |
| Q4 FY2020 | Dec 31, 2020 | $16.94M | -32.3% |
| Q3 FY2020 | Sep 30, 2020 | $18.96M | -24.0% |
| Q2 FY2020 | Jun 30, 2020 | $20.97M | -15.8% |
| Q1 FY2020 | Mar 31, 2020 | $22.99M | -7.5% |
| Q4 FY2019 | Dec 31, 2019 | $25.01M | +0.9% |
| Q3 FY2019 | Sep 30, 2019 | $24.95M | +209.1% |
| Q2 FY2019 | Jun 30, 2019 | $24.90M | +160.8% |
| Q1 FY2019 | Mar 31, 2019 | $24.84M | +125.6% |
| Q4 FY2018 | Dec 31, 2018 | $24.79M | +98.8% |
| Q3 FY2018 | Sep 30, 2018 | $8.07M | -42.0% |
| Q2 FY2018 | Jun 30, 2018 | $9.55M | -37.9% |
| Q1 FY2018 | Mar 31, 2018 | $11.01M | -34.5% |
| Q4 FY2017 | Dec 31, 2017 | $12.47M | -11.5% |
| Q3 FY2017 | Sep 30, 2017 | $13.92M | +18.2% |
| Q2 FY2017 | Jun 30, 2017 | $15.37M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.82M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.09M | – |
| Q3 FY2016 | Sep 30, 2016 | $11.78M | – |
See a number that looks wrong?